Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The health risks that can develop as a result of having more weight than normal have been listed below
Developed by Eli Lilly, retatrutide has been evaluated in Phase 2 clinical trials publishing some of the largest reported weight-reduction figures of any incretin-based compound to date, attributed to the added glucagon-receptor component, which is believed to increase energy expenditure alongside the appetite-suppressing and glycemic effects shared with GLP-1/GIP agonism
Are a current or past smoker
A doctor cannot legally prescribe an unapproved drug outside of a clinical trial setting
US$ 25.59
US$ 28.25
US$ 23.32
US$ 22.66
US$ 21.43
